RESEARCH ARTICLE

The gut microbial metabolic capacity of microbiome-humanized vs. wild type rodents reveals a likely dual role of intestinal bacteria in hepato-intestinal schistosomiasis

Alba Corteñes1,2, John Martin3, Bruce A. Rosa3, Klara A. Stark1, Simon Clare4,5, Catherine McCarthy6, Katherine Harcourt6, Cordelia Brandt6, Charlotte Tolley2,6, Trevor D. Lawley5, Makedonka Mitreva3, Matthew Berriman5, Gabriel Rinaldi5,6,*, Cinzia Cantacessi1,*,

1 Department of Veterinary Medicine, University of Cambridge, Cambridge, United Kingdom, 2 Department de Farmàcia, Tecnologia Farmacèutica i Parasitologia, Facultat de Farmàcia, Universitat de València, Burjasot, València, Spain, 3 Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America, 4 Department of Medicine, University of Cambridge, Cambridge, United Kingdom, 5 Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom, 6 Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, United Kingdom

* These authors contributed equally to this work.

¤ Current address: Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom

¤ Current address: Department of Life Sciences, Aberystwyth University, Aberystwyth, United Kingdom

*pi matt.berriman@glasgow.ac.uk (MB); gabriel.rinaldi@aber.ac.uk (GR); cc779@cam.ac.uk (CC)

Abstract

Increasing evidence shows that the host gut microbiota might be involved in the immunological cascade that culminates with the formation of tissue granulomas underlying the pathophysiology of hepato-intestinal schistosomiasis. In this study, we investigated the impact of Schistosoma mansoni infection on the gut microbial composition and functional potential of both wild type and microbiome-humanized mice. In spite of substantial differences in microbiome composition at baseline, selected pathways were consistently affected by parasite infection. The gut microbiomes of infected mice of both lines displayed, amongst other features, enhanced capacity for tryptophan and butyrate production, which might be linked to the activation of mechanisms aimed to prevent excessive injuries caused by migrating parasite eggs. Complementing data from previous studies, our findings suggest that the host gut microbiome might play a dual role in the pathophysiology of schistosomiasis, where intestinal bacteria may contribute to egg-associated pathology while, in turn, protect the host from uncontrolled tissue damage.

Author summary

Schistosomiasis is a neglected tropical disease affecting >250 million people worldwide. Causative agents are parasitic worms of the genus Schistosoma, that inhabit the small
blood vessels irrigating the gut and urinary bladder. Adult schistosomes lay their eggs that make their way to the environment by piercing the intestinal or urinary bladder wall to reach the host feces and urine, respectively. *Schistosoma* infections are associated with substantial alterations of gut bacterial communities of both naturally infected humans and experimentally infected mice. Intestinal bacteria are also hypothesized to contribute to the intestinal pathology caused by migrating parasite eggs. Here, we investigated the impact of schistosome infection on the composition and function of gut bacteria inhabiting wild type and microbiome-humanized laboratory rodents. Schistosome colonization was consistently associated with an increased (predicted) ability of gut bacteria to synthetize tryptophan and butyrate, both of which are known to promote intestinal barrier function by preventing translocation of potentially harmful bacteria into the circulation. Our findings suggest that intestinal bacteria may exert both harmful and protective roles during schistosomiasis, and provide a basis for the development of much needed novel and sustainable strategies for management and control of this neglected disease.

**Introduction**

Schistosomiasis, caused by blood flukes of the genus *Schistosoma*, is a neglected tropical disease affecting the world’s poorest communities [1]. Globally, >250 million people are infected with at least one of the three major species that infect humans—*S. mansoni*, *S. japonicum* and *S. haematobium*—mostly in regions of sub-Saharan Africa and focal areas of America, the Middle East and Asia [1]. Adult male and female worms dwell *in copula*, first in the portal system, and then, in the mesenteric or pelvic veins of their hosts. Fertilized females lay eggs that, following a migration through the lining of small venules, pierce the wall of the intestine (*S. mansoni* and *S. japonicum*) or the bladder (*S. haematobium*) to be released with the host feces or urine, respectively [1]. Subsequently, when eggs reach the freshwater environment, they hatch ciliated miracidia that seek out and infect snail intermediate hosts [1]. Inside the snail, the parasites undergo a phase of asexual reproduction, i.e., from mother and daughter sporocysts to free-living infectious cercariae that leave the snail to swim and seek the definitive mammalian host. The cercariae penetrate the host skin, shed their tails and become schistosomula that enter the circulation and migrate through the lungs, heart and liver, where they further develop into male and female worm pairs. Between 3 and 4 weeks post-infection, paired adult worms migrate to the mesenteric venules (*S. mansoni* and *S. japonicum*) or the venous plexus of the urinary bladder (*S. haematobium*) and begin to release hundreds of eggs per day [1].

The pathophysiology of acute schistosomiasis is mainly associated with parasite eggs becoming trapped in various organs and tissues (i.e., the intestine and liver, or the urinary bladder) and subsequent formation of inflammatory granulomas containing immune cells (alternatively activated macrophages, granulocytes, Th2 and B cells) and extracellular matrix [2]. During the chronic phase of infection, granulomas shrink and are replaced by fibrous tissue, that often compromises the function of affected organs [1].

The genesis of *Schistosoma* egg-induced granulomas is the result of a finely regulated cross-talk between egg-secreted antigens and host immunity [2,3]. However, over the last few years, evidence has emerged of the likely contribution of a third player—the host gut microbiota—in the cascade of immunological events that culminate with the formation of tissue granulomas [4–8]. First, in a seminal study conducted in murine schistosomiasis [4], administration of broad-spectrum antibiotics and antimycotics resulted in substantially decreased intestinal inflammation and granuloma development. In the same study, lymphocyte preparations from...
mesenteric lymph nodes retrieved from microbiota-depleted mice showed reduced production of IFN-γ and IL-10 when exposed to *S. mansoni* secreted egg antigen, thus indicating that gut resident bacteria may influence schistosome-specific immunity [4]. Supporting the hypothesis of a key role of the host gut microbiota in the pathophysiology of schistosomiasis, we previously detected dramatic alterations in the gut microbial profiles of mice during acute patent infection by *S. mansoni* compared with uninfected controls [5]; these alterations included substantially decreased and increased gut bacterial alpha- and beta diversity, respectively, as well as changes in the relative abundances of populations of microbes with putative roles in host immune-regulatory and/or inflammatory responses [5]. We therefore speculated that such changes, indicative of dysbiosis and accompanying egg migration across the gut wall and consequent immunopathology, might contribute to the pathophysiology of hepato-intestinal schistosomiasis [5]. In a subsequent study, we attempted to investigate the translational significance of these findings by characterizing the gut microbial profiles of microbiota-humanized [human-microbiota-associated (HMA)] and wild type (WT) mice prior to and following infection with *S. mansoni* [8]. High-throughput sequencing of the bacterial 16S rRNA gene revealed profound differences between the microbial profiles of these cohorts at baseline, with the gut microbiota of HMA being characterized by low microbial alpha diversity, expanded populations of Proteobacteria and absence of lactobacilli compared to WT rodents [8]. Of note, whilst *S. mansoni* infection was associated with a significant decrease in gut microbial alpha diversity in both rodent lines, analysis of bacterial taxa whose relative abundances were altered following worm colonization revealed substantial dissimilarities between HMA and WT mice [8]. Interestingly, significantly higher worm and egg burdens were recovered from HMA vs. WT at the end of the experiment [8]. Based on this observation, we hypothesized that the structure and function of the host baseline gut microbiome (i.e., prior to infection) might play a key role in the complex network of interactions between schistosome parasites, the host and its immune system. Whilst data from these studies represent a step forward in our current understanding of these relationships, the microbiota profiling techniques applied thus far (i.e., bacterial culturing followed by colony counting and bacterial 16S rRNA gene amplicon sequencing) [4,5,8] do not permit explorations of schistosomiasis-associated changes in gut bacterial populations beyond genus-level taxonomic mapping. Determining differences in gut microbial communities between schistosome-infected and -uninfected HMA and WT mice at species level, and evaluating the relative contribution of each community member to the overall pool of functional genes, are nonetheless pivotal. This knowledge is likely to unveil mechanisms underlying crosstalk between host, parasite and microbiome during schistosome infection.

In this study, we undertake high-throughput shotgun metagenomics sequencing of the gut microbiome of HMA and WT mice to provide a high-resolution map of the functional potential of gut bacterial communities established in these mouse lines. Furthermore, we investigate changes in the composition and functional potential of these communities following experimental infection with *S. mansoni*. We show that, despite profound differences in compositional and functional profiles between the two murine lines, parasite colonization induced partially overlapping alterations in bacterial metabolic capacity, including up-regulation of pathways linked to L-tryptophan biosynthesis and fermentation to short chain fatty acids (SCFAs).

**Results and discussion**

**Gut bacterial profiles differ between WT and HMA mice**

Whole genome sequencing (WGS) of fecal DNA extracts from both *S. mansoni*-infected (hereafter referred to as ‘Sm+’) and uninfected (‘Sm−’) WT and HMA mice yielded 228.03·10^6 ±
31.13 × 10^6 (mean ± standard deviation) reads per sample, while no-DNA template negative controls generated 10.56 × 10^3 ± 13.27 × 10^3 reads (S1 Fig). Mean base count per sample prior to and following quality filtering and removal of host sequences did not yield significant differences between mouse lines, nor between infection groups within each line (S1 Fig).

Taxonomic profiling of filtered metagenomic data identified a total of 449 bacterial species across samples encompassing both WT (418 species) and HMA mice (363 species); these belonged to 187 genera, of which 38 and 18 were unique to WT and HMA, respectively (S1 Table and S2 Fig). Substantial differences in both bacterial species composition and corresponding relative abundances were observed between the gut microbiomes of WT and HMA mice (Figs 1, S2 and S3), with HMA gut bacterial communities clustering separately from those of WT by Principal Coordinates Analysis (PCoA) (Fig 2A), as previously reported [8]. Moreover, microbial beta diversity in WT was significantly higher than that in HMA (cf. Fig 2A; ANOSIM: R = 1, p < 0.001), likely due to differences in breeding and housing conditions between these rodent lines (i.e., specific-pathogen-free environment for WT vs. isolation for HMA).

Species richness and alpha diversity (Shannon index) in the gut microbiome of WT were significantly higher than those in HMA (t-test p = 0.002, t = 3.362, df = 26; and p < 0.0001, t = 6.450, df = 26, respectively) (Fig 2B). This observation is in accordance with our previous marker-gene-based work, where significantly higher bacterial alpha diversity was observed in the gut microbiota of WT compared to HMA mice [8], a finding tentatively attributed to a likely failure of selected human gut microbes to colonize the mouse gastrointestinal (GI) tract [8]. Moreover, according to previous observations [8], substantial differences were detected in the relative abundances of predominant taxa in the GI tracts of WT and HMA (S2 Fig). For instance, several Bacteroides species, including B. cellulosilyticus, B. vulgatus, B. dorei and B. thetaiotaomicron, amongst others, predominated in HMA, whereas B. acidifaciens was significantly more abundant in WT mice. These differences, along with the absence of individual bacterial species (and/or genera) in the gut of WT or HMA mice, might impact the overall functional potential of the microbiomes of these mice, as well as of the microbiota-mediated immune modulation [9]. A striking example is represented by the genus Lactobacillus, whose members were only detected in the gut of WT animals (S1 Table). These bacteria are common inhabitants of mouse and human GI tracts, and their relative abundance frequently increases following microbial transfers between mice [10,11]; however, previous studies have reported a failure of members of Lactobacillaceae to engraft the colons of HMA mice following fecal material transplant of human feces containing lactobacilli [12]. Most lactobacilli produce lactate, that may be further fermented by other gut bacteria into butyrate, a SCFA with anti-inflammatory properties [13,14]. In addition, selected species and strains of Lactobacillus are responsible for activation of mechanisms of innate immunity in the host GI tract via toll-like receptor (TLR)-dependent and -independent pathways [15,16]. Interestingly, our previous data revealed higher S. mansoni infection burdens in HMA vs. WT mice, which led us to hypothesize the occurrence of a link between host baseline microbiota composition and susceptibility to infection [8]. Whilst attributing these observations to the absence of lactobacilli in the HMA gut is currently unwarranted, our data point toward this bacterial group as a potential target for future mechanistic studies aimed to elucidate these interactions.

The gut bacterial metagenomes of WT and HMA mice feature distinct functional profiles

We then performed functional annotations of gut metagenome data of both Sm+ and Sm- WT and HMA mice using established bioinformatics pipelines (see Materials and Methods).
The gut microbiome of *Schistosoma*-infected wildtype vs. microbiota-humanised mice.
Principal Component Analysis (PCA) applied to pathway abundance data separated the gut microbiomes of WT and HMA mice into two distinct clusters along PC1 (Fig 2C) [supported by Canonical Correspondence Analysis (CCA; p = 0.001, F = 64.9)], thus revealing profound differences in the overall functional profiles of bacterial communities colonizing the gut of each murine line.

A total of 289 metabolic pathways were identified by HUMAnN3 (https://huttenhower.sph.harvard.edu/humann/) in at least five samples of WT and/or HMA mice; of these, 244 and 276 were detected in the metagenomes of WT and HMA, respectively, and analyzed further (S4 Fig and S2 Table). Thirteen pathways were solely detected in the microbiomes of WT; these included, amongst others, ‘Bifidobacterium shunt’ (P124-PWY; a fermentation pathway for production of lactate and the SCFA acetate), ‘L-glutamate degradation IV’ (PWY-4321) and ‘spermine and spermidine degradation I’ (PWY-6117) (S2 Table). Notably, bacterial species contributing to pathways solely identified in WT remained mostly unclassified, except for *Lactobacillus reuteri*, which was associated with ‘L-glutamate degradation IV’ (PWY-4321), ‘superpathway of geranylgeranylphosphate biosynthesis I (via mevalonate)’ (PWY-5910) and ‘mevalonate pathway I (eukaryotes and bacteria)’ (PWY-922) (S2 Table). HUMAnN relies on the MetaPhlAn tool (https://huttenhower.sph.harvard.edu/metaphlan/) to identify bacterial organisms present in a given metagenome [17]. The MetaPhlAn algorithm estimates microbial taxa abundance based on the coverage of clade-specific marker genes that are present in all strains of a given species, thus representing a powerful strategy to generate unambiguous markers for genetic characterization of metagenomic species [17]. Such an approach, however, favors the identification of species with several strains for which complete genomes are available; thus, taxonomic annotation using this approach is likely to lead to the identification of a smaller number of species compared with WGS read-mapping against reference genomes in the GenBank database, as the latter contains sequences from several species with incomplete genome assemblies.

The 45 pathways uniquely identified in the microbiomes of HMA included eight superpathways for the biosynthesis of menaquinones [e.g., ‘superpathway of menaquinol-8 biosynthesis I’ (PWY-5838) and ‘superpathway of menaquinol-11 biosynthesis’ (PWY-5897)], several pathways involved in the synthesis of cell wall and outer membrane components [‘peptidoglycan biosynthesis IV (Enterococcus faecium)’ (PWY-6471), ‘peptidoglycan biosynthesis V (β-lactam resistance)’ (PWY-6470), ‘peptidoglycan biosynthesis II (staphylococci)’ (PWY-5265), ‘superpathway of UDP-glucose-derived O-antigen building blocks biosynthesis’ (PWY-7328) and ‘superpathway of dTDP-glucose-derived O-antigen building blocks biosynthesis (PWY-7317)]], and pathways for the degradation/utilization of carbohydrates, including ‘trehalose degradation V’ (PWY-2723), ‘glycogen degradation I’ (GLYOCAT-PWY), ‘starch degradation III’ (PWY-6731) and ‘glucose and glucose-1-phosphate degradation’ (GLUCOSE1PME-TAB-PWY). Similar to WT mice, bacterial species contributing to HMA-unique pathways remained largely unclassified (S2 Table).

Differences between the gut bacterial profiles of WT vs. HMA are likely to underpin profound functional dissimilarities between these communities. Other external factors that had shaped the composition of the donor microbiome inoculum prior to administration to HMA recipients (e.g., diet, feeding patterns and metabolic requirements, among others) might also contribute to these functional differences [18]. However, it is important to point out that such
**Fig 2.** Compositional and functional profiles of the gut metagenomes of wild type (WT) and human-microbiota-associated (HMA) mice. (A) Principal Coordinates Analysis (PCoA) of microbial community composition of all *Schistosoma*-infected and -uninfected animals in both experiments, determined by mapping of shotgun metagenomic reads against bacterial reference genomes available from the GenBank database. (B) Alpha diversity. (C) Principal Component Analysis (PCA) of pathway relative abundances at community-level as determined by HUMAnN3. Asterisks indicate significant differences between groups determined by unpaired t-test: **p < 0.01; ***p < 0.0001.

https://doi.org/10.1371/journal.pntd.0010878.g002
discrepancies may not be conclusively associated to the differences in *S. mansoni* infection burdens observed in WT vs. HMA mice [cf. 8], as similar end-products of microbiome metabolism could be generated via distinct biological pathways. For instance, the ‘Bifidobacterium shunt’ pathway detected in WT mice might be associated with enhanced ability to produce lactate/acetate (and thus, butyrate) [13,14]; however, several HMA-unique pathways for carbohydrates degradation (see above) might result in higher rates of pyruvate biosynthesis and, in turn, of SCFA production [19].

**Schistosoma mansoni** infection is associated with altered gut bacterial community structure and species composition in both WT and HMA mice

We subsequently focused on characterizing the effect(s) of *S. mansoni* infection on the gut bacterial community structure of each WT and HMA. Using PCoA, gut bacterial communities of both WT and HMA clustered by infection status, although only HMA *Sm*+ and *Sm*− samples grouped separately along the PCoA1 axis (Fig 3A and 3B). Microbial beta diversity was significantly higher across *Sm*+ samples of both WT (ANOSIM: R = 0.361, p < 0.004) and HMA (ANOSIM: R = 0.651, p < 0.002) compared to their uninfected counterparts. In contrast, Shannon index was unaltered following infection of either line, although a significant decrease in gut bacterial richness was observed in HMA at 50 days post *S. mansoni* colonization (t-test p = 0.014, t = 2.864, df = 12) (S5 Fig). Infections by *Schistosoma* spp. had been associated with significantly decreased gut bacterial richness and alpha diversity, and linked to local inflammation and tissue damage caused by migrating parasite eggs [5,7]. Differences in infection burdens [cf. 5] or *Schistosoma* species [cf. 7] used in these previous studies might hold partially accountable for this discrepancy. Nonetheless, our published 16S rRNA gene amplicon sequencing data had also revealed significant reductions in alpha diversity in WT and HMA mice infected with *S. mansoni* [8]. Hence, our current observations might be indicative of the fact that marker gene data may lead to an overestimation of the impact of the infection on gut bacterial alpha diversity.

Hierarchical clustering of WT and HMA gut microbiomes grouped HMA samples according to infection status, while WT *Sm*+ and *Sm*− samples remained partially intermingled; moreover, ordination of infected samples according to infection burdens [i.e., worm counts and/or eggs per gram (EPG) of liver] was not observed in either mouse line (Fig 1). In order to gain insights into species whose abundances were altered following *S. mansoni* infection, the relative abundances of identified bacteria were compared between *Sm*+ and *Sm*− mice of each line. Significant differences in bacterial species abundance associated with infection status were detected in both WT and HMA mice by Linear Discriminant Analysis Effect Size (LEfSe) and confirmed by Mann-Whitney U test; these alterations encompassed members of the genera *Bacteroides*, *Parabacteroides*, *Alistipes* and *Barnesiella* (Fig 3C and S3 Table), which had been previously reported to change in response to *S. mansoni* infection in WT and/or HMA mice in targeted metagenomics studies [5,6,8]. Furthermore, strong significant correlations (i.e., Pearson’s $r \geq [0.8]$, p < 0.001) were observed between selected bacterial species significantly impacted by infection (cf. Fig 3C) and parasite burdens (i.e., worm counts and/or EPG of liver; cf. [8]) in the two mouse lines (S4 Table).

Both *Bacteroides* and *Alistipes* harbor species with known anti-inflammatory properties, whilst expansions of selected members of each genus have been also linked to selected inflammatory conditions. For instance, *B. acidifaciens*, a species expanded in the gut of WT *Sm*+ mice, has been reported to overgrow following IL-22 blockage in a mouse model of chronic *Salmonella* gastroenteritis, ultimately leading to exacerbated intestinal inflammation [20]. Additional studies, however, have demonstrated protective effects of this bacterial species
The gut microbiome of Schistosoma-infected wildtype vs. microbiota-humanised mice

### WT

| Bacterial species                          | Associated group |
|--------------------------------------------|------------------|
| Bacteroides acidifaciens                  | Sm+              |
| Bacteroides caecimuris                    | Sm-              |
| Bacteroides caecimuri                     |                  |
| Alistipes dispar                           |                  |
| Alistipes shahii WAL 8301                  |                  |
| Alistipes senegalensis JC50                |                  |
| Alistipes finegoldii DSM 17242             |                  |
| Parabacteroides distasonis ATCC 8503       |                  |
| Alistipes pravencessis                     |                  |
| Lactobacillus reuteri DSM 20016            |                  |
| Lactobacillus johnsonii NCC 533           |                  |
| Alistipes megapd                       |                  |
| Alistipes timonensis JC136                 |                  |
| bacterium 1xD42 87                        |                  |
| bacterium D16 29                          |                  |
| Muribaculaceae bacterium                   |                  |
| Schaedlerella arabinosiphila               |                  |

### HMA

| Bacterial species                          | Associated group |
|--------------------------------------------|------------------|
| Parbacteroides goldsteinii DSM 19448 = WAL 12034 | Sm+   |
| Barnesiella intestinibominis YIT 11860       | Sm-   |
| Bacteroides sartori                         |                  |
| Bacteroides uniformis                       |                  |
| Bacteroides cellulosilyticus                |                  |
| Bacteroides rodentium JCM 16496             |                  |
| Bacteroides timonensis                      |                  |
| Bacteroides xylanisolvens                   |                  |
| Bacteroides intestinalis                    |                  |
| Bacteroides stercorirostris JCM 17103       |                  |

### LDA score (log10)

- <2.5
- 2.5-3.0
- >3
against liver inflammation and allergic asthma that may be mediated by the production of SCFAs [21,22]. Remarkably, expansion of B. acidifaciens and increased butyrate production were linked to enhanced gut barrier integrity and function. Similarly, while several Alistipes species have been linked to the gut of healthy and diseased individuals [23], oral gavage with A. finegoldii (significantly expanded in WT Sm+) was associated with protection against colitis in mice [24].

Some Bacteroides species, whose abundances were reduced upon S. mansoni infection in HMA, have been reported to exert anti-inflammatory effects in rodent models of intestinal inflammation, and/or when administered as probiotics; e.g., B. uniformis [25,26], and B. cellulosolyticus [27]. However, intriguingly, these changes were accompanied by a significant expansion of P. goldsteinii (Fig 3C), whose relative abundance had been negatively correlated with fecal levels of lipocalin-2 (a marker of intestinal inflammation) in mice genetically susceptible to colitis [28]. This association suggested a protective effect of P. goldsteinii against colitis, which was tentatively attributed to the ability of this bacteria to produce SCFAs [29], as well as to promote regulatory IL-10 and reduce proinflammatory IL-1β and intestinal permeability [30,31]. Expansions of the genus Parabacteroides were previously linked to S. mansoni infection in both HMA and WT mice [8]. However, our current data show that, unlike in HMA, expansion of this genus in the gut of WT Sm+ mice was mainly linked to P. distasonis (Fig 3C), whose roles in health and disease may vary depending on bacterial strain- and host-related factors [32].

Additionally, previously unreported expansions of the Lactobacillus species L. reuteri and L. johnsonii were observed in the gut microbiomes of WT Sm+ mice compared with uninfected counterparts (Fig 3C). Alterations of GI populations of lactobacilli have been described in several rodent models of helminth colonization, including mice infected with S. mansoni [reviewed in 33]. In particular, a transient expansion of Lactobacillus spp. was reported in mice prior to the onset of egg laying by S. mansoni, that was however not maintained post-egg laying [5]. Likewise, our previously published targeted metagenomics data did not reveal significant alterations in the abundance of Lactobacillus post egg-laying [8]. Hence, current data pointing towards expanded populations of selected lactobacilli following S. mansoni infection might be indicative of a role of these bacteria in the pathophysiology of schistosomiasis, and are thus worth exploring. Indeed, the roles of lactobacilli in mediating protection against GI inflammation have been extensively described [34,35]. For instance, L. reuteri exerts protective effects against chemically-induced experimental colitis via reduced leukocyte recruitment, platelet-mediated inflammation and bacterial translocation [36,37]; similarly, L. johnsonii has been demonstrated to exert protective anti-inflammatory activity against bacterial colitis in mice [38]. Moreover, the occurrence of a mutualistic relationship between gut lactobacilli and the GI nematode Heligmosomoides polygyrus was proposed in a seminal study showing that supplementation of L. taiwanensis promoted chronic helminth establishment via Treg expansion in rodent mesenteric lymph nodes [39]. Whether L. reuteri and/or L. johnsonii play a role in regulating host immunity and/or local inflammation in hepato-intestinal schistosomiasis is yet to be determined. However, remarkably, loss of lactobacilli in antibiotic-treated mice recolonized by co-housing with S. mansoni-infected rodents resulted in increased susceptibility to DSS-induced colitis, when compared to microbiota-depleted mice co-housed with uninfected controls [6].
Altogether, observed changes in the composition of the gut microbiota at species-level resolution suggest that several bacteria might be selectively expanded in the gut of WT and HMA mice following *S. mansoni* infection, and assist with protection against egg-mediated tissue damage and inflammation. However, given that the impact of *S. mansoni*-induced intestinal pathology and immune environment on the protective effects of some of these bacteria is difficult to assess [20], and that such protective effects might be associated with specific strains of these bacterial species [32], this hypothesis remains to be thoroughly tested. Indeed, not only determining individual species whose abundances are affected by *S. mansoni* infection, but also their contribution to intestinal protection/damage is essential to gain new insights onto the role(s) of gut bacteria in the pathophysiology of schistosomiasis.

**Schistosomiasis is associated with alterations of the gut microbial functional profiles of WT and HMA mice**

The gut bacterial metagenomes of HMA and WT mice were clustered according to their predicted metabolic profiles by pathway abundance data, stratified by known and unclassified organisms. PCA revealed marked differences between the gut bacterial functional profiles of HMA *Sm*− and HMA *Sm*+, that were supported by CCA (F = 5.29, p = 0.001; Fig 4A). In contrast, WT samples clustered by experiment (S6 Fig), rather than by infection status (Fig 4A), with minimal overlap. Accordingly, CCA yielded significant differences in WT gut microbial metabolic profiles according to experiment (F = 3.05, p = 0.002), but not to infection (F = 1.49, p = 0.128).

Metabolic pathways detected in at least 5 metagenomes of either HMA or WT were analyzed for correlation with *S. mansoni* infection by MaAsLin2 and LEfSe on unstratified data. The complete lists of metabolic pathways associated with the gut metagenomes of *Sm*+ and *Sm*− of each WT and HMA, by MaAsLin2 and/or LEfSe, are available from S5 and S6 Tables, respectively. A total of 31 metabolic pathways were consistently associated with *S. mansoni* infection in WT mice by both MaAsLin2 (p<0.05; FDR q-value>0.05 for all features) and LEfSe [Linear Discriminant Analysis (LDA) score (log)>2]. In particular, 21 pathways were overrepresented in the gut microbiomes of WT *Sm*+, and 10 in the microbiomes of WT *Sm*− (S5 Table). In HMA, 50 metabolic pathways were consistently associated with *S. mansoni* infection by both MaAsLin2 and LEfSe (S6 Table). Of these, 19 were overrepresented in the gut microbiomes of HMA *Sm*+ mice, and 31 in the microbiomes of HMA *Sm*−. In both mouse lines, most of the metabolic pathways altered by *S. mansoni* infection could be grouped into three functional categories: (i) biosynthesis, (ii) degradation/utilization/assimilation and/or (iii) generation of precursor metabolites and energy (S5 and S6 Tables). Eleven metabolic pathways displayed significant changes with *S. mansoni* infection in both WT and HMA (S7 Table); of these, 3 were consistently altered by infection in both WT and HMA, including a pathway for the biosynthesis of L-tryptophan (i.e., TRPSYN-PWY) (Fig 4B). Moreover, the gut microbiomes of both WT *Sm*+ and HMA *Sm*+ displayed an enhanced (predicted) ability to produce selected SCFAs, albeit via different metabolic pathways (Fig 4C). Together, these findings point towards a likely functional link between *Schistosoma* infection and the production of selected microbial metabolites as result of the dynamic cross-kingdom interaction in the gut.

**Enhanced potential for L-tryptophan biosynthesis and butyrate production in both schistosoma-infected WT and HMA mice**

*S. mansoni* infection was shown to significantly impact gut microbial amino acid metabolism in both WT and HMA hosts (S5 and S6 Tables), although several pathways changed in
The gut microbiome of *Schistosoma*-infected wildtype vs. microbiota-humanised mice

### A

WT

HMA

### B

**TRPSYN-PWY**

- Lachnospiraceae bacterium A4
- Lachnospiraceae bacterium 101
- Bacteroides vulgatus
- Others
- Unclassified

### C

**WT**

**HMA**

- Flavonifractor plautii
- Dorea sp CAG 317
- Anaerotruncus sp G3 2012
- Hungatella hathewayi
- Clostridium aldenense
- Others
- Unclassified
opposite directions following parasite colonization in each mouse line (S7 Fig). In particular, ‘superpathway of L-serine and glycine biosynthesis I’ (SER-GLYSYN-PWY), ‘L-ornithine biosynthesis II’ (ARGININE-SYN4-PWY), and ‘GABA shunt’ (GLUDEG-I-PWY; a pathway for L-glutamate degradation) were enriched in the microbiome of WT Sm+ compared with WT Sm-, and in HMA Sm- compared with HMA Sm+. In addition, ‘L-methionine biosynthesis III’ (HSERMETANA-PWY) and ‘L-arginine biosynthesis II (acetyl cycle)’ (ARGSYNBSUB-PWY) were significantly enriched in HMA Sm+ (S7 Fig). In contrast, ‘L-tryptophan biosynthesis’ (TRPSYN-PWY) was consistently linked to S. mansoni infection in both WT and HMA mice (Fig 4B). Expansion of this pathway in WT Sm+ mice was linked to two Lachnospiraceae bacteria (i.e., A4 and 101) as well as to Bacteroides vulgatus; nonetheless, the individual contribution of these bacteria to the overrepresentation of the pathway was not statistically significant (Fig 4B). In HMA, in contrast, expansion of TRPSYN-PWY following infection was significantly linked to B. vulgatus, together with other low abundant bacteria (Fig 4B).

The microbial metabolism of amino acids plays key roles in the maintenance of gut barrier integrity and immune homeostasis [40]. For instance, polyamines derived from arginine and ornithine metabolism enhance gut barrier function by inducing overexpression of tight junction proteins and reducing inflammation [41–43]. For these reasons, an enhanced metabolism of these amino acids by the gut microbiome has been linked to a ‘healthy’ gut [44,45]. Given the differences detected between WT vs. HMA hosts in infection-associated alterations in arginine/ornithine/polyamine metabolism (S7 Fig and S5 and S6 Tables), caution is warranted when discussing any role(s) of these amino acids and corresponding metabolites in the context of schistosomiasis. However, the enhanced capacity for bacterial tryptophan biosynthesis detected in both rodent lines following S. mansoni infection may suggest a likely link between parasite infection and luminal production of this essential amino acid that, under physiological conditions, is mainly of dietary acquisition [46]. Both host- and microbiota-derived tryptophan metabolites are involved in the regulation of several host functions, including immune regulation by RORγt(+)-IL-22(+)-type 3 innate lymphoid cells (ILC3s) and maintenance of gut barrier function [46,47]. Hence, the enrichment of the ‘L-tryptophan biosynthesis’ pathway in the gut microbiomes of both WT and HMA mice following S. mansoni infection raises the question of whether this might serve as a compensatory mechanism to counteract local tissue damage caused by the migration of schistosome eggs through the intestinal wall. Future studies, including targeted perturbation of the ‘L-tryptophan biosynthesis’ pathway [e.g., 48] in the context of schistosome infection are needed to address this question.

Only a few gut resident bacteria, including selected species of the phyla Firmicutes and Bacteroidetes, are currently known to metabolize luminal tryptophan into indole and its derivatives [49]; these molecules may promote intestinal epithelial cell (IEC) renewal, barrier integrity, and maintenance of immune homeostasis via the activation of aryl hydrocarbon receptor (AhR) signaling in intestinal epithelial and mucosal immune cells [46,47]. Our analysis did not detect any pathway for tryptophan degradation; nevertheless, significant expansions of the tryptophan metabolizing species P. distasonis, L. reuteri and L. johnsonii [49] were
observed in the gut of WT mice following infection by *S. mansoni* (Fig 3C). Interestingly, populations of *L. reuteri*, but not of *L. johnsonii*, are known to expand in response to increased luminal tryptophan availability, and catabolize tryptophan into indole derivatives via aromatic amino acid aminotransferase [50]. In turn, *L. reuteri* mediates reprogramming of intraepithelial CD4+ T cells into immunoregulatory CD4+CD8αα+ T cells via production of indole derivatives and activation of AhR signaling [51], and induces innate IL-22 production in the mouse gut by ILC3s, thus promoting gut barrier function [50]. IL-22 regulates production of antimicrobial peptides (AMPs) in the gut [52]. Strikingly, antibody-mediated neutralization of this cytokine was associated with the expansion of gut populations of *B. acidifaciens* in a murine model of *Salmonella* infection, an effect that was linked to an altered production of IL-22-regulated AMPs (i.e., Reg3β) [20]. In a different study, however, IL-22-mediated AMP responses led to a significant reduction of *Bacteroides* and the expansion of *Lactobacillus* [53]. Our finding of a concomitant expansion of *B. acidifaciens* along with several tryptophan metabolizing bacteria (i.e., *P. distasonis*, *L. reuteri* and *L. johnsonii*) in the gut of WT *Sm*+ reveals a complex scenario, where both parasite-specific- and microbiota-modulated-immunity are likely to influence populations of selected microbial species. Future studies addressing the contribution of selected members of the gut microbiome to the local immune response during intestinal schistosomiasis will assist to disentangle the intricate interplay between parasite infection, these bacteria, and host immunity.

In addition to tryptophan metabolites, microbiota-derived SCFAs, and butyrate in particular, are involved in the regulation of AhR and its target genes in both liver and intestine [54,55]. In addition, butyrate promotes gut barrier integrity by modulating transcription factors in IECs (i.e., activating HIF1, STAT3 and SP1, and inhibiting NF-κB) and mediates anti-inflammatory functions by signaling on innate and adaptive immune cells [19]. Metabolic pathways involved in the production of butyrate were overrepresented in the gut microbiome of both WT and HMA mice following infection with *S. mansoni*. In particular, the pathways ‘acetyl-CoA fermentation to butanoate II’ (PWY-5676) and ‘4-aminobutanoate degradation V’ (PWY-5022) were enriched in the gut microbiomes of HMA *Sm*+ and WT *Sm*+ mice, respectively, compared to their uninfected counterparts (Fig 4C and S5 and S6 Tables). The gut microbiome of WT *Sm*+ was also enriched in the ‘GABA shunt’ pathway, whose products (i.e., 4-aminobutanoate and succinate) are metabolized to butyrate through the ‘4-aminobutanoate degradation V’ pathway (cf. S5 Table). Furthermore, the gut microbiomes of infected animals of both host lines displayed enhanced potential for production of acetate and/or lactate, that are both key substrates for butyrate-producing bacteria [13,14,56,57]. In particular, the pathways ‘pyruvate fermentation to acetate and lactate II’ (PWY-5100) and ‘acetylene degradation (anaerobic)’ (P161-PWY) were enriched in HMA *Sm*+, whereas ‘homolactic fermentation’ (ANAEROFRUCAT-PWY) was overrepresented in WT *Sm*+ (Fig 4C and S5 and S6 Tables). Specific bacteria linked to these functions remained largely unclassified both in WT and HMA mice (Fig 4C). Nevertheless, a significant contribution of *Flavonifractor plautii* to PWY-5676 was observed in HMA *Sm*+, whereas *Dorea* sp CAG 317, *F. plautii* and *Hungatella hathewayi* were significantly linked to the overrepresentation of PWY-5100 in the gut of the same animals (Fig 4C).

Additional pathways related to SCFA production were underrepresented in both WT *Sm*+ and HMA *Sm*+, compared to uninfected counterparts. In particular, the pathways ‘hexitol fermentation to lactate, formate, ethanol and acetate’ (P461-PWY) and ‘succinate fermentation to butanoate’ (PWY-5677) were enriched in the gut microbiomes of WT *Sm*+ and HMA *Sm*+, respectively (S5 and S6 Tables). Nonetheless, these pathways were comparatively less abundant than those involved in the same metabolic processes (i.e., lactate/acetate and butyrate biosynthesis) and that were overrepresented in *Sm*+ of the corresponding host line (Fig 4C).
Metabolic profiling of biofluids had already revealed alterations of gut microbial metabolites in mice infected with *S. mansoni*, including SCFAs [58,59]. In particular, acetate, propionate and butyrate were depleted in urine samples of infected mice at 7 weeks post-infection, which suggested either a reduced production of these SCFAs by gut bacteria or an increased utilization of these metabolites by the vertebrate host [58]. In support of the latter hypothesis, in a separate study, significantly increased levels of propionate were detected in feces of *Sm*+ between 7 and 9 weeks post-infection, although no statistically significant differences in butyrate levels were detected between infected mice and uninfected controls [59]. The discrepancies between data from our study and that by Li et al. [59] might be linked to differences between mouse strains [C57BL/6 vs. NMRI, respectively] and/or other factors known to affect the composition of the host gut microbiota, such as age or diet [18]. Nonetheless, observations from both our study and that by Li et al. [59] support a link between *S. mansoni* infection and enhanced SCFAs biosynthesis in the rodent gut.

**Schistosomiasis may be associated with reduced horizontal gene transfer within the microbiota of HMA mice**

The relative abundances of the top 10,000 functionally annotated gene families identified by HUMAnN3 in at least 5 metagenomes of either HMA or WT were compared between *Sm*+ and *Sm*- by MaAsLin2 and LEfSe. The substantial differences in the microbiomes of WT mice between the two independent experiments performed (‘B1’ and ‘B2’; cf. Materials and Methods) impaired the optimal fitting of the linear model (LM) calculated by MaAsLin2 to determine associations between gene family abundances and *S. mansoni* infection in these mice. Therefore, in order to overcome this technical limitation, the MaAsLin2 output was compared with that obtained by LEfSe; this approach led to the identification of 3 gene families whose relative abundances were altered by *S. mansoni* infection according to both MaAsLin2 (q<0.05) and LEfSe (LDA score (log)>2). These gene families, enriched in the gut microbiome of WT *Sm*+ mice compared to WT *Sm*-, encoded for 2 proteins involved in chromosome segregation (i.e., chromosome partitioning and ParB-like partition proteins) and a TraG-like protein involved in conjugative plasmid transfer (S8 Table). A total of 6 and 62 gut microbial gene families were enriched in HMA *Sm*+ and HMA *Sm*-, respectively, by both MaAsLin2 (q<0.01) and LEfSe (LDA score (log)>2) (S9 Table). Notably, amongst the latter, there were several families with roles in plasmid biology, including genes encoding proteins involved in conjugative plasmid transfer (e.g., MobA, MobB and MobC, amongst others), plasmid recombination (i.e., plasmid recombination enzyme family proteins), initiation of plasmid replication and plasmid copy control (e.g., protein involved in initiation of plasmid replication and RepA) (S9 Table).

Plasmids mediate horizontal gene transfer (HGT) between bacteria [60]. A recent study has revealed that HGT occurs frequently within individual human gut microbiomes, although frequency is higher in industrialized urban populations than in non-industrialized rural communities [61]. The specific factors responsible for such differences are currently unknown; however, it has been speculated that alterations in the gut ecosystem linked, for instance, to the dramatic changes in dietary and sanitation habits experienced throughout the industrialization process, rather than variations in bacterial species composition, are likely to be held accountable [61]. Improved sanitation in tropical and subtropical impoverished areas of the world has led to a significantly reduced risk of infection with many parasitic worms, including *Schistosoma* spp. [62]. Hence, the significance of our observation that several gene families related to regulation of plasmid transfer were underrepresented in the gut of HMA *Sm*+ mice is worth exploring. It is well established that, within the gut microbiota, antimicrobial resistance
(AMR) genes are maintained and exchanged via HGT among bacterial communities [63]. A recent report showed no significant association between gut microbiota, AMR genes and urogenital schistosomiasis in preschool-aged children [64]. However, further studies are needed to determine whether hepato-intestinal schistosomiasis might represent an additional factor limiting HGT, thus impacting on the distribution of AMR genes in the host gut. Interestingly, we identified a number of gene families related to resistance against several classes of antibiotics, including beta-lactams, fluoroquinolones, tetracyclines, aminoglycosides, macrolides and chloramphenicol (S10 Table) and detected significant differences (by MaAsLin2 only) in the abundance of 9 families linked to AMR in HMA mice (S9 Table). In particular, these gene families, all of which were significantly associated with the gut microbiome of HMA Sm- mice, encoded for proteins involved in resistance against beta-lactams (4 families), macrolides (3 families), tetracyclines and chloramphenicol (1 family each).

Concluding remarks

In this study, we investigated the impact of S. mansoni infection on the gut microbial composition and predicted functions of two mouse lines with significant differences in their baseline gut microbial communities (i.e., WT and HMA). Comparisons of gut microbial functional profiles between Sm+ and Sm- mice revealed infection-associated alterations in both hosts, some of which were consistently associated with worm colonization, whereas others displayed opposite trends in each infection model. Occurrence of consistent microbiome alterations in response to infection suggest a fine crosstalk between S. mansoni and the host gut microbiome. In particular, our findings support the hypothesis that gut microbial responses to S. mansoni infection might involve enhanced production of tryptophan metabolites and butyrate, and subsequent activation of AhR signaling and further butyrate-regulated pathways, in order to limit helminth-induced tissue damage. These findings offer a novel and intriguing perspective on the role(s) of the host gut microbiome in the pathophysiology of schistosomiasis, including its likely contribution to Schistosoma egg-induced intestinal pathology and inflammation in infected hosts [4,6]. Indeed, together with those previous reports, our current results point toward a likely dual role of the gut microbiome in the pathophysiology of schistosomiasis, where intestinal bacteria may contribute to egg-associated intestinal pathology while, simultaneously, protect the host from excessive tissue damage. This data may open new avenues towards the discovery of tentative bacterial targets for innovative control strategies, that are desperately needed for this neglected tropical disease. In addition, our preliminary observation that schistosomiasis mansoni might impact HGT in the vertebrate gut microbiota offers an intriguing insight into helminth-microbiota relationships, and calls for future investigations aimed to assess the role(s) that helminth infections might play in gene flow and spread of AMR in both rodent models and natural hosts.

Materials and methods

Ethics statement

The life cycle of S. mansoni (NMRI strain) was maintained at the Wellcome Sanger Institute (WSI) by breeding and infecting susceptible intermediate (Biomphalaria glabrata) snails and definitive hosts (female TO mice). All experimental infections and regulated procedures described in this study were approved by the Animal Welfare and Ethical Review Body (AWERB) of WSI. All experiments were conducted under Home Office Project Licenses (Procedure Project License—PPL) No. P77E8A062 held by Gabriel Rinaldi, and No. P6D3B94CC held by Trevor D. Lawley. The AWERB is constituted as required by the UK Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012.
**Experimental procedures**

Detailed methods for generating and breeding HMA mice, production of *S. mansoni* infective stages, experimental infections and parasitological procedures are available from Cortés et al. [8]. Briefly, 200 μl homogenates obtained from fresh feces from a healthy human donor were administered to 5 male and 5 female C57BL/6 germ-free mice by oral gavage once a week, for 3 weeks. Mice were subsequently set up as breeding pairs in a decontaminated positive pressure isolator. HMA mice used in this study belonged to the fourth generation of breeding animals; these were removed from the isolator in sealed ISOcages and maintained on a positive pressure ISOrack (Tecniplast) for use in the experiments described below. A total of 8 HMA and 8 WT mice (female C57BL/6, bred at the WSI) were infected percutaneously with 80 *S. mansoni* cercariae (*Sm*+), as described previously [65] and maintained for 50 days with access to food and water *ad libitum*. Six HMA and WT mice, respectively, were kept uninfected and used as negative controls (*Sm*−). Two independent experiments were performed (identified as 'B1' and 'B2', respectively) using identical procedures as described above. Experiment B1 included 5 *Sm*+ and 3 *Sm*− of each HMA and WT, while experiment B2 included 3 *Sm*+ and 3 *Sm*− of each HMA and WT [8]. All mice were euthanized 50 days post-infection, and adult worms recovered from *Sm*+ mice via portal perfusion [65]. Control *Sm*− mice were perfused as the infected animals. Fecal pellets were collected directly from the colons of individual mice at necropsy; pellets were transferred to sterile tubes, snap frozen on dry ice, and stored at -80°C until DNA isolation, which was performed within 3 weeks from sample collection.

**DNA extraction and shotgun metagenomics sequencing**

Genomic DNA was isolated from a total of 28 colonic content samples and 4 no-DNA template negative controls from both independent experiments, using the PowerSoil DNA Isolation Kit (QIAGEN) according to manufacturers’ instructions. DNA was prepared and sequenced at WSI using the Illumina Hi-Seq platform with library fragment sizes of 200–300 bp and a read length of 100 or 125 bp, as previously described [66].

**Bioinformatics analyses, statistics and reproducibility**

WGS reads were subjected to quality and adapter trimming using Trim Galore (version 0.4.0) using default parameters, and paired reads of <20 bp for at least one of the two sequences were removed (https://github.com/FelixKrueger/TrimGalore; [67]). Quality-filtered reads were mapped against the *Mus musculus* reference genome (GRChm38 assembly) using the BWA-MEM algorithm [68]. Clean reads were mapped against reference bacterial genomes available from GenBank (S1 Table) and, for each sample, microbial community composition was defined based on the relative abundance of each genome displaying breadth coverage ≥1% and depth coverage >0.01X (S1 Table); the gut microbial communities of *Sm*− and *Sm*+ HMA and WT mice were compared using the online software MicrobiomeAnalyst [69]. In particular, following CSS data normalization, samples were clustered by PCoA based on Bray-Curtis dissimilarities, and differences in beta diversity between groups were assessed by Analysis of Similarity (ANOSIM) [70]. Differences in microbial species richness and Shannon index between groups were assessed by unpaired t-test. Furthermore, heatmaps displaying Pearson correlation between community composition and explanatory variables, i.e., mouse line (WT and HMA), infection status (*Sm*+ and *Sm*−) and experiment (B1 and B2) were generated; significant alterations in the relative abundances of microbial taxa following experimental *S. mansoni* infection were determined by LEfSe [71] and Mann-Whitney U test. Occurrence of linear relationships between the relative abundance (logarithmic) of gut bacterial species significantly impacted by *S. mansoni* infection, as well as infection burdens (i.e., worm counts and EPG of liver; cf. [8]),
was tested by Pearson correlation and the statistical significance of the Pearson correlation coefficient (r) was assessed by two-tailed t-test.

Functional annotations of gut metagenome data were performed using HUMAnN3 [72], ran from the biobakery/humann docker container (latest version as of October 2020) using the Chocophlan nucleotide database and Uniref90 protein database [73]. HUMAnN3 runs the Metaphlan program as an intermediate step to assign organism-specific functional profiling, which was performed using the developer-provided MetaPhlAn3 bowtie2 database [17,74]. Additional scripts embedded within HUMAnN3 (humann_rename_table and human_join_table) were used to align gene family descriptions and merge the 128 original output gene family abundance tables into a single table. The HUMAnN3 pipeline also provided MetaCyc [75] pathway abundance detected per sample. HUMAnN’s default Reads Per Kilobase (RPK) values for gene family and pathway abundances were transformed into copies per million (CPM) units using the “humann_renorm_table” script (included in the HUMAnN3 distribution; S10 and S12 Tables) and associations between the predicted functional properties of each metagenome and S. mansoni infection in either HMA and WT mice were assessed by PCA and CCA using Calypso [76]. Biological pathways and gene families significantly enriched in the metagenomes of either Sm- or Sm+ mice (HMA and WT, respectively) were determined using MaAsLin2 [77], by applying the LM with default settings (except for the analysis of gene families, prior to which data were log-transformed); potential differences between samples collected in each independent experiment were taken into account by fixing this variable as a random effect. Furthermore, pathway and gene family relative abundances were compared between Sm+ and Sm- of each HMA and WT using the LEfSe workflow [71] implemented in Galaxy (https://huttenhower.sph.harvard.edu/galaxy/), setting the variable “experiment” as subgroup for comparisons. Both pathway and gene family detection for a given rodent line was defined when confirmed in at least 5 out of the 14 samples analyzed per line.

Supporting information

S1 Fig. Whole genome sequencing output. (A) Read counts obtained from fecal DNA extracts of wild type (WT) and human-microbiota-associated (HMA) mice, and negative controls (i.e., no-DNA template; NC); *p<0.05, **p<0.01 and ns = not significant by post hoc Dunn’s test. (B) and (C) Base counts prior to (= sequenced) and following quality filtering and removal of host sequences (= filtered) according to mouse line and infection status, respectively. Differences between groups were assessed by Mann-Whitney U test. Sm+ = Schistosoma mansoni-infected; Sm- = S. mansoni-uninfected.

S2 Fig. Gut microbiota composition of wild type (WT) and human-microbiota-associated (HMA) mice. (A) Venn diagram indicating the total number of bacterial species and corresponding genera identified in the metagenomes of WT and/or HMA mice following mapping of shotgun metagenomic reads against bacterial reference genomes available from the GenBank database. (B) Relative abundances of the 30 most abundant species.

S3 Fig. Gut microbiota composition of wild type (WT) and human-microbiota-associated (HMA) mice. Relative abundances, per sample, of the 30 most abundant bacterial species. Samples are hierarchically clustered according to Pearson correlation between species relative abundances, and explanatory variables are indicated at the top of the figure (i.e., mouse line, infection status and infection burdens; cf. Fig 1. EPG = eggs per gram).
S4 Fig. Gut bacterial functional profiles in wild type (WT) vs. human-microbiota-associated (HMA) mice. Venn diagram indicating the total number of bacterial metabolic pathways identified by HUMAnN3 in the gut metagenomes of at least five samples of WT and/or HMA mice.

(SPS)

S5 Fig. Gut bacterial alpha diversity in *Schistosoma mansoni* infected (Sm+) and uninfected (Sm-) mice. Shannon diversity and species richness in Sm+ and Sm- samples of (A) wild type (WT) and (B) human-microbiota-associated (HMA) mice. Asterisks indicate significant differences between groups determined by unpaired t-test: "p<0.05.

(SPS)

S6 Fig. Fecal metabolic profiles of wild type (WT) mice. Principal Component Analysis (PCA) of the fecal metabolic profiles of WT mice according to experiment and infection status (Sm+ = *Schistosoma mansoni*-infected; Sm- = uninfected controls).

(SPS)

S7 Fig. Gut bacterial capacity for amino acid metabolism in wild type (WT) and human-microbiota-associated (HMA) mice. For each mouse line, only differentially abundant pathways between *S. mansoni* infected (Sm+) and uninfected (Sm-) animals (cf. S5 and S6 Tables) are shown.

(SPS)

S1 Table. List of bacterial genomes detected in fecal samples of wild type (WT) and/or human-microbiota-associated (HMA) mice by mapping of reads against reference bacterial genomes available from the GenBank database. Only genomes displaying mean breadth coverage ≥1% and mean depth coverage >0.01X were considered in each mouse line.

nd = not detected.

(XLSX)

S2 Table. Metabolic pathways. (A) Metabolic pathways identified in at least 5 fecal samples of wild type (WT) and/or human-microbiota-associated (HMA) mice by HUMAnN3. (B) Metabolic pathways identified only in WT samples, stratified by known and unclassified organisms. (C) Metabolic pathways identified only in HMA samples, stratified by known and unclassified organisms.

(XLSX)

S3 Table. Bacterial species in wild type (WT) and human-microbiota-associated (HMA) mice. Results of LEfSe and Mann-Whitney U test applied to the identification of differentially abundant bacterial species between the gut microbial communities of *Schistosoma mansoni*-infected (Sm+) and uninfected (Sm-) WT and HMA mice.

(XLSX)

S4 Table. Correlation between gut bacterial abundance and infection burdens. Pearson correlation between the relative abundance of gut bacterial species significantly impacted by *Schistosoma mansoni* infection in wild type (WT) and human-microbiota-associated (HMA) mice (cf. Fig 3) and infection burdens (i.e., worm counts and eggs per gram (EPG) of liver; cf. [8]).

(XLSX)

S5 Table. Metabolic pathways in wild type (WT) mice. Differentially abundant metabolic pathways between the gut microbiomes of *Schistosoma mansoni*-infected (Sm+) and -uninfected (Sm-) WT mice by MaAsLin2 (p<0.05) and/or LEfSe [LDA score (log)>2]. For each pathway, mean abundance and standard deviation (SD), fold change between groups, and
functional classification according to MetaCyc database are provided. Fold change $<0 =$ overrepresented in $Sm-$; fold change $>0 =$ overrepresented in $Sm+$.

**S6 Table. Metabolic pathways in human-microbiota-associated (HMA) mice.** Differentially abundant metabolic pathways between the gut microbiomes of *Schistosoma mansoni*-infected ($Sm+$) and -uninfected ($Sm-$) HMA mice by MaAsLin2 ($p<0.05$) and/or LefSe [LDA score (log)$>2$]. For each pathway, mean abundance and standard deviation (SD), fold change between groups, and functional classification according to MetaCyc database are provided. Fold change $<0 =$ overrepresented in $Sm-$; fold change $>0 =$ overrepresented in $Sm+$.

**S7 Table. Metabolic pathways in both wild type (WT) and human-microbiota-associated (HMA) mice.** Differentially abundant metabolic pathways [MaAsLin2 $p<0.05$ and LefSe LDA score (log)$>2$] between the gut microbiomes of both WT and HMA mice infected by *Schistosoma mansoni* ($Sm+$) and matched uninfected controls ($Sm-$). For each pathway, functional classification according to MetaCyc database and fold change between infected and uninfected animals of each line are indicated. Fold change $<0 =$ overrepresented in $Sm-$; fold change $>0 =$ overrepresented in $Sm+$.

**S8 Table. Gene families in wild type (WT) mice.** Differentially abundant gene families between the gut microbiomes of *Schistosoma mansoni*-infected ($Sm+$) and uninfected ($Sm-$) WT mice, by MaAsLin2 ($q<0.05$) and/or LefSe [LDA score (log)$>2$]. For each family, mean relative abundance, standard deviation (SD) and fold change between $Sm-$ and $Sm+$ are provided.

**S9 Table. Gene families in human-microbiota-associated (HMA) mice.** Differentially abundant gene families between the gut microbiomes of *Schistosoma mansoni*-infected ($Sm+$) and -uninfected ($Sm-$) HMA mice, by MaAsLin2 ($q<0.01$) and/or LefSe [LDA score (log)$>2$]. For each family, mean relative abundance, standard deviation (SD) and fold change between $Sm-$ and $Sm+$ are provided.

**S10 Table. Gene family abundances.** Relative abundances (in CPM; copies per million) of gene families computed by HUMAnN3 at community level for each sample included in this study.

**S11 Table. Mapping results.** Results of mapping of whole genome shotgun sequencing reads against reference bacterial genomes available from GenBank.

**S12 Table. Metabolic pathway abundance.** Relative abundances [in CPM (copies per million) and for each sample included in this study] of metabolic pathways identified by HUMAnN3 at community level using gene abundances along with the structure of the pathway (based on MetaCyc pathway definitions).

**Acknowledgments**

The authors would like to thank Mandy Sanders (Wellcome Sanger Institute) for technical assistance.
Author Contributions

Conceptualization: Alba Cortés, Gabriel Rinaldi, Cinzia Cantacessi.

Data curation: Alba Cortés, John Martin, Bruce A. Rosa.

Formal analysis: Alba Cortés, John Martin, Bruce A. Rosa, Klara A. Stark.

Funding acquisition: Alba Cortés, Matthew Berriman, Gabriel Rinaldi, Cinzia Cantacessi.

Methodology: Alba Cortés, Simon Clare, Catherine McCarthy, Katherine Harcourt, Cordelia Brandt, Charlotte Tolley, Gabriel Rinaldi.

Project administration: Gabriel Rinaldi, Cinzia Cantacessi.

Validation: Alba Cortés, John Martin, Bruce A. Rosa.

Visualization: Alba Cortés, John Martin, Bruce A. Rosa, Klara A. Stark.

Writing – original draft: Alba Cortés, Cinzia Cantacessi.

Writing – review & editing: Alba Cortés, John Martin, Bruce A. Rosa, Klara A. Stark, Simon Clare, Catherine McCarthy, Katherine Harcourt, Cordelia Brandt, Charlotte Tolley, Trevor D. Lawley, Makedonka Mitreva, Matthew Berriman, Gabriel Rinaldi, Cinzia Cantacessi.

References

1. McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou X-N. Schistosomiasis. Nat Rev Dis Primer 2018; 4: 13.
2. Costain AH, MacDonald AS, Smits HH. Schistosome egg migration: Mechanisms, pathogenesis and host immune responses. Front Immunol 2018; 9: 3042. https://doi.org/10.3389/fimmu.2018.03042 PMID: 30619372
3. Takaki KK, Rinaldi G, Berriman M, Pagán AJ, Ramakrishnan L. Schistosoma mansoni/eggs modulate the timing of granuloma formation to promote transmission. Cell Host Microbe 2021; 29: 58–67.e5. https://doi.org/10.1016/j.chom.2020.10.002 PMID: 33120115
4. Holzscheiter M, Layland LE, Loffredo-Verde E, Mair K, Vogelmann R, Langer R, et al. Lack of host gut microbiota alters immune responses and intestinal granuloma formation during schistosomiasis. Clin Exp Immunol 2014; 175: 246–57. https://doi.org/10.1111/cei.12230 PMID: 24168057
5. Jenkins TP, Peachey LE, Ajami NJ, MacDonald AS, Hsieh MH, Brindley PJ, et al. Schistosoma mansoni infection is associated with quantitative and qualitative modifications of the mammalian intestinal microbiota. Sci Rep 2018; 8: 12072. https://doi.org/10.1038/s41598-018-30412-x PMID: 30104612
6. Floudas A, Aviello G, Schwartz C, Jeffery IB, O'Toole PW, Fallon PG. Schistosoma mansoni worm infection regulates the intestinal microbiota and susceptibility to colitis. Infect Immun 2019; 87: e00275–19. https://doi.org/10.1128/IAI.00275-19 PMID: 31136116
7. Zhao Y, Yang S, Li B, Li W, Wang J, Chen Z, et al. Alterations of the mice gut microbiome via Schistosoma japonicum ova-induced granuloma. Front Microbiol 2019; 10: 352. https://doi.org/10.3389/fmicb.2019.00352 PMID: 30991012
8. Cortés A, Clare S, Costain A, Almeida A, McCarthy C, Harcourt K, et al. Baseline gut microbiota composition is associated with Schistosoma mansoni infection burden in rodent models. Front Immunol 2020; 11: 593838. https://doi.org/10.3389/fimmu.2020.593838 PMID: 33329584
9. Brown RL, Larkinson MLY, Clarke TB. Immunological design of commensal communities to treat intestinal infection and inflammation. PLoS Pathog 2021; 17: e1009191. https://doi.org/10.1371/journal.ppat.1009191 PMID: 33465156
10. Ellekilde M, Selfjord E, Larsen CS, Jaksevecic M, Rune I, Tranberg B, et al. Transfer of gut microbiota from lean and obese mice to antibiotic-treated mice. Sci Rep 2014; 4: 5922. https://doi.org/10.1038/srep05922 PMID: 25082483
11. Lundberg R, Toft MF, Metzdorf SB, Hansen CHF, Licht TR, Bahl MI, et al. Human microbiota-transplanted C57BL/6 mice and offspring display reduced establishment of key bacteria and reduced immune stimulation compared to mouse microbiota-transplantation. Sci Rep 2020; 10: 7805. https://doi.org/10.1038/s41598-020-64709-3 PMID: 32385373
12. Petursdottir DH, Nordlander S, Qazi KR, Carvalho-Queiroz C, Ahmed Osman O, Hell E, et al. Early-life human microbiota associated with childhood allergy promotes the Th17 helper axis in mice. Front Immunol 2017; 8: 1699. https://doi.org/10.3389/fimmu.2017.01699 PMID: 29250074

13. Bourraud C, Robins RJ, Martin L, Kozlowski F, Tenailleau E, Cherbut C, et al. Lactate is mainly fermented to butyrate by human intestinal microfloras but interindividual variation is evident. J Appl Microbiol 2005; 99: 201–12. https://doi.org/10.1111/j.1365-2672.2005.02605.x PMID: 15960680

14. Iraporda C, Errea A, Romanin DE, Cayet D, Pereyra E, Pignataro O, et al. Lactate and short chain fatty acids produced by microbial fermentation downregulate proinflammatory responses in intestinal epithelial cells and myeloid cells. Immunobiology 2015; 220: 1161–9. https://doi.org/10.1016/j.imbio.2015.06.004 PMID: 26101138

15. Smelt MJ, de Haan BJ, Bron PA, van Swam I, Meijerink M, Wells JM, et al. L. plantarum, L. salivarius, and L. lactis attenuate Th2 responses and increase Treg frequencies in healthy mice in a strain dependent manner. PLoS One 2012; 7: e47244. https://doi.org/10.1371/journal.pone.0047244 PMID: 23056616

16. Ren C, Zhang Q, de Haan BJ, Zhang H, Faas MM, de Vos P. Identification of TLR2/TLR6 signalling lactate acid bacteria for supporting immune regulation. Sci Rep 2016; 6: 34561. https://doi.org/10.1038/srep34561 PMID: 27708357

17. Beghini F, McVey LJ, Blanco-Miguez A, Dubois L, Asnicar F, Maharjan S, et al. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with BioBakery. 3. eLife 2021; 10: e65088. https://doi.org/10.7554/eLife.65088 PMID: 33944776

18. Nguyen TLA, Vieira-Silva S, Liston A, Raes J. How informative is the mouse for human gut microbiota research? Dis Model Mech 2015; 8: 1–16. https://doi.org/10.1242/dmm.017400 PMID: 25561744

19. Deleu S, Machiels K, Raes J, Verbeke K, Vermeire S. Short chain fatty acids and its producing organisms: An overlooked therapy for IBD? EBioMedicine 2021; 66: 103293. https://doi.org/10.1016/j.ebiom.2021.103293 PMID: 33813134

20. Lo BC, Shin SB, Canals Hernaez D, Refaeli I, Yu HB, Goebeler V, et al. IL-22 preserves gut epithelial integrity and promotes disease remission during chronic *Salmonella* infection. J Immunol Baltim Md 1950 2019; 202: 956–65. https://doi.org/10.4049/jimmunol.1801308 PMID: 30617224

21. Aoki R, Onuki M, Hattori K, Ito M, Yamada T, Kamikado K, et al. Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice. Microbiome 2021; 9: 188. https://doi.org/10.1186/s40168-021-01125-7 PMID: 34530928

22. Alharris E, Mohammed A, Alghetaa H, Zhou J, Nagarkatti M, Nagarkatti P. The ability of resveratrol to attenuate ovalbumin-mediated allergic asthma is associated with changes in microbiota involving the gut-lung axis, enhanced barrier function and decreased inflammation in the lungs. Front Immunol 2022; 13: 805770. https://doi.org/10.3389/fimmu.2022.805770 PMID: 35265071

23. Parker BJ, Wearsch PA, Veloo ACM, Rodriguez-Palacios A. The genus *Alistipes*: gut bacteria with emerging implications to inflammation, cancer, and mental health. Front Immunol 2020; 11: 906. https://doi.org/10.3389/fimmu.2020.00906 PMID: 32582143

24. Dziarski R, Park SY, Kaayhpy DR, Dowd SE, Gupta D. Pglyrp-regulated gut microflora *Prevotella falsenii, Parabacteroides distasonis* and *Bacteroides eggerthii* enhance and attenuate intestinal inflammation. J Immunol 2015; 195: 806–16. https://doi.org/10.4049/jimmunol.1500627 PMID: 26727499

25. Fabersani E, Portune K, Campillo I, López-Almeja I, Le Paz SM, Romaní-Pérez M, et al. *Bacteroides uniformis CECT 7771* alleviates inflammation within the gut-adipose tissue axis involving TLR5 signaling in obese mice. Sci Rep 2021; 11: 11778. https://doi.org/10.1038/s41598-021-90888-y PMID: 34083551

26. López-Almeja I, Romaní-Pérez M, Bullich-Villarrubias C, Benítez-Páez A, Gómez Del Pulgar EM, Francés R, et al. *Bacteroides uniformis* combined with fiber amplifies metabolic and immune benefits in obese mice. Gut Microbes 2021; 13: 1–20. https://doi.org/10.1080/19490076.2020.1865706 PMID: 33499721

27. Neff CP, Rhodes ME, Arnolds KL, Collins CB, Donnelly J, Nusbacher N, et al. Diverse intestinal bacteria contain putative zwitterionic capsular polysaccharides with anti-inflammatory properties. Cell Host Microbe 2016; 20: 535–47. https://doi.org/10.1016/j.chom.2016.09.002 PMID: 27693306

28. Tsou AM, Goettel JA, Bao B, Biswas A, Kang YH, Redhu NS, et al. Utilizing a reductionist model to study host-microbe interactions in intestinal inflammation. Microbiome 2021; 9: 215. https://doi.org/10.1186/s40168-021-01161-3 PMID: 34732258

29. Biggs MB, Medlock GL, Moutinho TJ, Lees HJ, Swann JR, Kolling GL, et al. Systems-level metabolism of the altered Schaedler flora, a complete gut microbiota. ISME J 2017; 11: 426–38. https://doi.org/10.1038/ismej.2016.130 PMID: 27824342
30. Wu T-R, Lin C-S, Chang C-J, Lin T-L, Martel J, Ko Y-F, et al. Gut commensal *Parabacteroides goldsteinii* plays a predominant role in the anti-obesity effects of polysaccharides isolated from *Hirsutella sinensis*. Gut 2019; 68: 248–62. https://doi.org/10.1136/gutjnl-2017-315458 PMID: 3007918

31. Lai H-C, Lin T-L, Chen T-W, Kuo Y-L, Chang C-J, Wu T-R, et al. Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory *Parabacteroides goldsteinii* lipopolysaccharide. Gut 2022; 71: 309–21. https://doi.org/10.1136/gutjnl-2020-322599 PMID: 33687943

32. Ezeji JC, Sarikonda DK, Hopperton A, Erkkila HL, Cohen DE, Martinez SP, et al. *Parabacteroides distasonis*: intriguing aerotolerant gut anaerobe with emerging antimicrobial resistance and pathogenic and probiotic roles in human health. Gut Microbes 2021; 13: 1922241. https://doi.org/10.1080/19490976.2021.1922241 PMID: 34196581

33. Cortés A, Peachey L, Scotti R, Jenkins TP, Cantacessi C. Helminth-microbiota cross-talk–A journey through the vertebrate digestive system. Mol Biochem Parasitol 2019; 233: 111222. https://doi.org/10.1016/j.molbiop.2019.111222 PMID: 31541662

34. Rooks MG, Garrett WS. Gut microbiota, metabolites and host immunity. Nat Rev Immunol 2016; 16: 341–52. https://doi.org/10.1038/nri.2016.42 PMID: 27231050

35. Zhang M, Wang H, Tracey KJ. Regulation of macrophage activation and inflammation by spermine: a new chapter in an old story. Crit Care Med 2000; 28: N60–6. https://doi.org/10.1097/00003246-200004001-00007 PMID: 10807317

36. Chen J, Rao JN, Zou T, Liu L, Marasa BS, Xiao L, et al. Polyamines are required for expression of Toll-like receptor 2 modulating intestinal epithelial barrier integrity. Am J Physiol Gastrointest Liver Physiol 2007; 293: G568–76. https://doi.org/10.1152/ajpgi.00201.2007 PMID: 1760044

37. Liu L, Guo X, Rao JN, Zou T, Xiao L, Yu T, et al. Polyamines regulate E-cadherin transcription through c-Myc modulating intestinal epithelial barrier function. Am J Physiol Cell Physiol 2009; 296: C801–10. https://doi.org/10.1152/ajpcell.00620.2008 PMID: 19176757

38. Qi H, Li Y, Yun H, Zhang T, Huang Y, Zhou J, et al. *Lactobacillus* maintains healthy gut mucosa by producing L-Orotate. Commun Biol 2019; 2: 171. https://doi.org/10.1038/s42003-019-0424-4 PMID: 31098404

39. Pruss KM, Enam F, Battaglioli E, DeFeo M, Diaz OR, Higginbottom SK, et al. Oxidative ornithine metabolism supports non-inflammatory *C. difficile* colonization. Nat Metab 2022; 4: 19–28. https://doi.org/10.1038/s42255-021-00506-4 PMID: 34992297

40. Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 2018; 23: 716–24. https://doi.org/10.1016/j.chom.2018.05.003 PMID: 29992437

41. Gao J, Xu K, Liu H, Liu G, Bai M, Peng C, et al. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front Cell Infect Microbiol 2018; 8: 13. https://doi.org/10.3389/fcimb.2018.00013 PMID: 29468141

42. Trondle J, Schoppel K, Bleidt A, Trachtmann N, Sprenger GA, Weuster-Botz D. Metabolic control analysis of L-tryptophan production with *Escherichia coli* based on data from short-term perturbation experiments. J Biotechnol 2020; 307: 15–28. https://doi.org/10.1016/j.jbiotec.2019.10.009 PMID: 31639341
49. Gasaly N, de Vos P, Hermoso MA. Impact of bacterial metabolites on gut barrier function and host immunity: a focus on bacterial metabolism and its relevance for intestinal inflammation. Front Immunol 2021; 12: 658354. https://doi.org/10.3389/fimmu.2021.658354 PMID: 34122415

50. Zelante T, Ianotti RG, Cuna C, De Luca A, Giovannini G, Pieraccini G, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 2013; 39: 372–85. https://doi.org/10.1016/j.immuni.2013.08.003 PMID: 23973224

51. Cervantes-Barragan L, Chai JN, Tianero DNM, Munk P, Mduluza T, Petersen TN, Brinch C, Ivens A, et al. The gut microbiome but not the resistome is associated with urogenital schistosomiasis control. PLoS Negl Trop Dis 2014; 8: e2651.

52. Keir M, Yi T, Lu T, Ghiardi N. The role of IL-22 in intestinal health and disease. J Exp Med 2020; 217: e20192195. https://doi.org/10.1084/jem.20192195 PMID: 32997932

53. Wang Q, Kim SY, Matsushita H, Wang Z, Pandeyarajan V, Matsuda M, et al. Oral administration of PEGylated TLR7 ligand ameliorates alcohol-associated liver disease via the induction of IL-22. Proc Natl Acad Sci U S A 2021; 118: e2020868118. https://doi.org/10.1073/pnas.2020868118 PMID: 33443222

54. Korecka A, Dona A, Lahiri S, Tett AJ, Al-Asmak M, Braniste V, et al. Bidirectional communication between the Aryl hydrocarbon Receptor (AhR) and the microbiome to host metabolism. NPJ Biofilms Microbiomes 2016; 2: 16014. https://doi.org/10.1038/npjbiofilms.2016.14 PMID: 28721249

55. Marinielli L, Martin-Gallausiaux C, Bourhis J-M, Bégue-Crespel F, Blottière HM, Lapaque N. Identification of the novel role of butyrate as AhR ligand in human intestinal epithelial cells. Sci Rep 2019; 9: 643. https://doi.org/10.1038/s41598-018-37019-2 PMID: 30679727

56. Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 2016; 7: 189–200. https://doi.org/10.1080/19490976.2015.1134082 PMID: 26963409

57. Rios-Covián D, Guermone M, Duncan SH, Flint HJ, de los Reyes-Gavilan CG. Enhanced butyrate formation by cross-feeding between Faecalibacterium prausnitzii and Bifidobacterium adolescentis. FEMS Microbiol Lett 2015; 362: fnv176. https://doi.org/10.1093/femsle/fnv176 PMID: 26420851

58. Wang Y, Holmes E, Nicholson JK, Cloarec O, Chollet J, Tanner M, et al. Metabonomic investigations in mice infected with Schistosoma mansoni: an approach for biomarker identification. Proc Natl Acad Sci U S A 2004; 101: 12676–81. https://doi.org/10.1073/pnas.0404878101 PMID: 15314325

59. Li JV, Saric J, Wang Y, Keiser J, Utzinger J, Holmes E. Chemometric analysis of biofluids from mice experimentally infected with Schistosoma mansoni. Parasit Vectors 2011; 4: 179.

60. Narra HP, Ochman H. Of what use is sex to bacteria? Curr Biol 2006; 16: R705–10. https://doi.org/10.1016/j.cub.2006.08.024 PMID: 16950097

61. Néraudeau D, Cui JQ, Walls A, et al. Water, Sanitation, and Hygiene (WASH): a critical component for sustainable soil-transmitted helminth and schistosomiasis control. PLoS Negl Trop Dis 2011; 5: e1000077.

62. Anthony WE, Burnham C-AD, Dantas G, Kwon JH. The gut microbiome as a reservoir for antimicrobial resistance. J Infect Dis 2021; 223: S209–13. https://doi.org/10.1093/infdis/jiaa497 PMID: 33326581

63. Harris SR, Feil EJ, Holden MTG, Quail MA, Nickerson EK, Hantratt P, et al. Evolution of MRSA during hospital transmission and intercontinental spread. Science 2010; 327: 469–74. https://doi.org/10.1126/science.1182395 PMID: 20093474

64. Crozier C, Brandt C, Rinaldi G, McCarthy C, Barker C, Clare S, et al. Screening of systemic immunity: a focus on bacterial metabolism and its relevance for intestinal inflammation. Front Immunol 2019; 4: 159. https://doi.org/10.3389/fimmu.2019.01597 PMID: 3126881

65. Crozier C, Brandt C, Rinaldi G, McCarthy C, Barker C, Clare S, et al. Screening of systemic immunity: a focus on bacterial metabolism and its relevance for intestinal inflammation. Front Immunol 2019; 4: 159. https://doi.org/10.3389/fimmu.2019.01597 PMID: 3126881

66. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. ArXiv13033997 Q-Bio [Internet] 2013[cited 2022 Apr 18]; Available from: http://arxiv.org/abs/1303.3997

67. Chong J, Liu P, Zhou G, Xia J. Using MicrobiomeAnalyst for comprehensive statistical, functional, and meta-analysis of microbiome data. Nat Protoc 2020; 15: 799–821.
70. Clarke KR. Non-parametric multivariate analyses of changes in community structure. Aust J Ecol 1993; 18: 117–43.
71. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, Huttenhower C. Metagenomic biomarker discovery and explanation. Genome Biol 2011; 12: R60. https://doi.org/10.1186/gb-2011-12-6-r60 PMID: 21702898
72. Franzosa EA, McIver LJ, Rahnavard G, Thompson LR, Schirmer M, Weingart G, et al. Species-level functional profiling of metagenomes and metatranscriptomes. Nat Methods 2018; 15: 962–8.
73. Suzek BE, Wang Y, Huang H, McGarvey PB, Wu CH, UniProt Consortium. UniRef clusters: a comprehensive and scalable alternative for improving sequence similarity searches. Bioinforma Oxf Engl 2015; 31: 926–32.
74. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012; 9: 357–9.
75. Caspi R, Billington R, Keseler IM, Kothari A, Krummenacker M, Midford PE, et al. The MetaCyc database of metabolic pathways and enzymes—a 2019 update. Nucleic Acids Res 2020; 48: D445–53. https://doi.org/10.1093/nar/gkz862 PMID: 31586394
76. Zakrzewski M, Proietti C, Ellis JJ, Hasan S, Brion M-J, Berger B, et al. Calypso: a user-friendly web-server for mining and visualizing microbiome-environment interactions. Bioinformatics 2017; 33: 782–3. https://doi.org/10.1093/bioinformatics/btw252 PMID: 28025202
77. Mallick H, Rahnavard A, McIver LJ, Ma S, Zhang Y, Nguyen LH, et al. Multivariable association discovery in population-scale meta-omics studies. PLoS Comput Biol 2021; 17: e1009442.